Overall, breast cancer, particularly the ER+ HER2− sub-group, due to the relatively low rate of tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment (TME), is considered scarcely or moderately immunogenic. This evidence concerns the gene ERBB2 and breast carcinoma.